Company News
On March 21, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the company will present the preclinical research data of IMM47 (CD24 antibody), IMM40H (CD70 antibody), IMM2520 (CD47×PD-L1), and IMM2902 (CD47×Her2) in the form of posters at the 2023 American Association for Cancer Research (AACR 2023) Annual Meeting in Orlando, Florida from April 14th to 19th.
For more information
Please follow the official wechat public account